perinatal collaborative care has been associated with improvements in mental health outcomes in randomized trials, not all referred women engage in the care provided. Untreated antenatal mental health disorders are associated with lack of initiation and early discontinuation of breastfeeding. Our objective was to examine whether engagement of women with a mental illness referred antenatally to a perinatal collaborative care program was associated with differences in breastfeeding intention and continuation, and whether any observed association was mediated by changes in depressive symptoms. STUDY DESIGN: This retrospective cohort study included all women who were referred antenatally by their obstetrician to a perinatal collaborative care program and who delivered viable infants between January 2017 and June 2018. Women were dichotomized by whether they engaged in collaborative care services, defined as participation in either therapy and/or medication management services. Breastfeeding intention (endorsed at delivery) and continuation at the postpartum visit were compared between women who did and did not engage in collaborative care by using bivariable and multivariable analyses. Mediation analyses were performed to determine if any observed associations were mediated by improvements or remission in depressive symptoms. RESULTS: Of the 340 eligible women referred to the perinatal collaborative care program, 264 (75.4%) engaged in the program. Compared to women who did not engage, women who engaged were more likely to intend breastfeeding [168 (95%) vs 47 (87%), p¼0.046] and to continue breastfeeding at the postpartum visit [92 (74%) vs 20 (53%), p¼0.012]. These associations persisted after controlling for potential confounders (Table) and were not mediated by improvements or remission in depressive symptoms. CONCLUSION: While antenatal mental health disorders are a risk factor for lack of intention or early cessation of breastfeeding, engagement in a collaborative care program is associated with improvement in both breastfeeding intention and continuation, independent of the mental health benefits. Milk samples were retained for analysis. Expressed milk was not given to infants during the study. Plasma and breast milk were analyzed for allopregnanolone concentrations. Brexanolone iv safety and tolerability were monitored throughout the study. RESULTS: Plasma concentrations of allopregnanolone increased during dose titration and declined during dose taper, with an average steady state concentration (C avg ) of 70.56 ng/mL (95% CI 61.8-80.4), a t 1/2 of 11.3 hours (95% CI 9.8-13.1), and an area under the curve to infinity (AUC N) of 3736.5 ng$h/mL (95% CI 3309.1-4219.1). Breast milk concentrations of allopregnanolone followed a similar pattern and fell below the limit of detection (5 ng/mL) in the majority of the women by approximately 3 days after infusion cessation.
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Overall pharmacokinetics results showed a rapid equilibrium between milk and plasma. The milk to plasma ratio appeared to be constant over a large range of plasma concentrations, with varying volumes of milk expressed and across subjects. There were no deaths, serious or severe adverse events, or clinically significant changes in safety tests, including laboratory results. CONCLUSION: Allopregnanolone concentrations were detected in breast milk of women receiving brexanolone iv. Concentrations in milk followed plasma concentrations closely, with rapid decline after the end of the 60-hour infusion to undetectable levels 3 days after the end of the infusion. There was no apparent accumulation of allopregnanolone in plasma or breast milk. OBJECTIVE: To provide a thorough description of maternal, fetal and neonatal outcomes associated with primary hyperparathyroidism (pHPT) in the contemporary setting, permitting a better understanding of the implication of pHPT in pregnancy. STUDY DESIGN: A retrospective case series at a Canadian tertiary-care referral center including 23 pregnancies in 19 women diagnosed with pHPT either pre-conceptionally, during gestation or within 6 weeks postpartum. An extensive evaluation of perinatal outcomes is presented. RESULTS: Over a period of 17.5-years, 19 women (with 23 pregnancies) were diagnosed with pHPT; typically mid-pregnancy. Most women (79%) were symptomatic at presentation, though often with non-specific manifestations. While 14% of pregnancies were affected by maternal/obstetric complications, fetal complications were observed in 45% of pregnancies for which data were available. Mild hypercalcemia (with accompanied hypophosphatemia in 46% and hypomagnesemia in 36%) was present in 57%, yet surgical intervention was the treatment of choice in 89%, and no complications were encountered. In contrast, of the two medically managed women with mild hypercalcemia, one term infant required NICU admission for hypercalcemia. Normal calcium levels in those treated before conception did not fully eliminate perinatal risk.
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